PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29261715
OWN - NLM
STAT- MEDLINE
DCOM- 20180108
LR  - 20180108
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 12
DP  - 2017
TI  - Gender-specific differences in the incidence of microalbuminuria in metabolic
      syndrome patients after treatment with fimasartan: The K-MetS study.
PG  - e0189342
LID - 10.1371/journal.pone.0189342 [doi]
AB  - BACKGROUND: The effect of resolving metabolic syndrome on target organ damage in 
      hypertensive patients is not well described. We evaluated whether treating
      metabolic syndrome (MetS) with an angiotensin receptor blocker subsequently
      reduced microalbuminuria in the K-MetS cohort. METHODS: Among 10,601 total
      metabolic syndrome patients, 3,250 (52.2% male, 56.2+/-10.0 years) with
      sufficient data on five specific metabolic components were included in this
      study. Patients were divided into four groups based on MetS status at baseline
      and 3 months. All patients received an angiotensin receptor blocker, fimasartan, 
      for these 3 months; thereafter, treatment was modified at the discretion of each 
      patient's physician. Microalbuminuria and the albumin/creatine ratio were
      evaluated as a proxy of organ damage. RESULTS: Blood pressure and waist
      circumference decreased from baseline to 3 months and 1 year. The average
      albumin/creatinine ratio significantly improved during the first three months of 
      the study from 36.0+/-147.4 to 21.0+/-74.9 mg/g (p<0.05) and was persistently
      high in patients with MetS at baseline and 3 months versus other groups. Women in
      comparison with men showed significantly lower ACR among patients with newly
      developed MetS at 3-month. CONCLUSIONS: Treatment of hypertensive patients for
      one year with the angiotensin receptor blocker fimasartan significantly reduced
      the albumin/creatine ratio, irrespective of whether the patient had MetS;
      however, the albumin/creatinine ratio was significantly higher in patents with
      persistent or newly developed MetS compared to patients without MetS.
      Additionally, these findings were more prominent in women than in men.
FAU - Park, Jeong Bae
AU  - Park JB
AUID- ORCID: http://orcid.org/0000-0002-5623-7010
AD  - JB lab and clinic, Seoul, South Korea.
AD  - Department of Medicine, Cheil General Hospital, Dankook University College of
      Medicine, Seoul, South Korea.
FAU - Kim, Su-A
AU  - Kim SA
AD  - Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan
      University School of Medicine, Seoul, South Korea.
FAU - Sung, Ki-Chul
AU  - Sung KC
AD  - Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung
      Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
FAU - Kim, Jang Young
AU  - Kim JY
AD  - Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju 
      College of Medicine, Gangwon-do, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20171219
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Albumins)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Pyrimidines)
RN  - 0 (Tetrazoles)
RN  - AYI8EX34EU (Creatinine)
RN  - P58222188P (fimasartan)
SB  - IM
MH  - Albumins/metabolism
MH  - Albuminuria/*drug therapy/*epidemiology/physiopathology
MH  - Biphenyl Compounds/*therapeutic use
MH  - Blood Pressure
MH  - Creatinine/metabolism
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Metabolic Syndrome/*drug therapy/*epidemiology/physiopathology
MH  - Middle Aged
MH  - Pyrimidines/*therapeutic use
MH  - *Sex Characteristics
MH  - Sex Factors
MH  - Tetrazoles/*therapeutic use
PMC - PMC5736217
EDAT- 2017/12/21 06:00
MHDA- 2018/01/09 06:00
CRDT- 2017/12/21 06:00
PHST- 2017/06/22 00:00 [received]
PHST- 2017/11/22 00:00 [accepted]
PHST- 2017/12/21 06:00 [entrez]
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
AID - 10.1371/journal.pone.0189342 [doi]
AID - PONE-D-17-23733 [pii]
PST - epublish
SO  - PLoS One. 2017 Dec 19;12(12):e0189342. doi: 10.1371/journal.pone.0189342.
      eCollection 2017.